Journal ArticleOPEN ACCESS

Glucosylated Epigallocatechin Gallate (EGCG) Derivatives Combined with EGFR Tyrosine Kinase Inhibitor Overcome Resistance in EGFR T790M Mutant Lung Cancer

  • Zi C
Biomedical Journal of Scientific & Technical Research (2019) 18(2)
DOI: 10.26717/bjstr.2019.18.003133
N/ACitations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Abstract

EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are approved treatments for non-small cell lung cancers harboring activating mutation...

Cite

CITATION STYLE

APA

Zi, C.-T. (2019). Glucosylated Epigallocatechin Gallate (EGCG) Derivatives Combined with EGFR Tyrosine Kinase Inhibitor Overcome Resistance in EGFR T790M Mutant Lung Cancer. Biomedical Journal of Scientific & Technical Research, 18(2). https://doi.org/10.26717/bjstr.2019.18.003133

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free